BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25455899)

  • 1. Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer.
    Ema A; Yamashita K; Ushiku H; Kojo K; Minatani N; Kikuchi M; Mieno H; Moriya H; Hosoda K; Katada N; Kikuchi S; Watanabe M
    Cancer Sci; 2014 Dec; 105(12):1591-600. PubMed ID: 25455899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
    Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
    Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust vascular invasion concurrent with intense EGFR immunostaining can predict recurrence in patients with stage IB node-negative gastric cancer.
    Araki I; Washio M; Yamashita K; Hosoda K; Ema A; Mieno H; Moriya H; Katada N; Kikuchi S; Watanabe M
    Surg Today; 2018 May; 48(5):478-485. PubMed ID: 29256147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
    Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
    Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
    Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
    Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
    J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients.
    Cao GD; Chen K; Chen B; Xiong MM
    BMC Cancer; 2017 Dec; 17(1):841. PubMed ID: 29233126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential role of Her3 in two signaling transduction patterns: Her2/Her3 and MET/Her3 in proliferation of human gastric cancer.
    Yun C; Gang L; Rongmin G; Xu W; Xuezhi M; Huanqiu C
    Mol Carcinog; 2015 Dec; 54(12):1700-9. PubMed ID: 25400108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of HER3 is associated with a decreased survival in gastric cancer.
    Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
    Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance of human epidermal growth factor receptor family molecules expression in gastric cancer].
    Li G; Gu RM; Wen X; Ming XZ; Xia L; Xu XY; Zhang J; Chen HQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jul; 16(7):668-72. PubMed ID: 23888453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of Ephrin A2 receptors in cancer stromal cells is a prognostic factor for the relapse of gastric cancer.
    Kikuchi S; Kaibe N; Morimoto K; Fukui H; Niwa H; Maeyama Y; Takemura M; Matsumoto M; Nakamori S; Miwa H; Hirota S; Sasako M
    Gastric Cancer; 2015 Jul; 18(3):485-94. PubMed ID: 24908114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma.
    Elebro J; Heby M; Warfvinge CF; Nodin B; Eberhard J; Jirström K
    PLoS One; 2016; 11(4):e0153533. PubMed ID: 27070783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER3 expression is correlated to distally located and low-grade colon cancer.
    Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
    Acta Oncol; 2016 Jul; 55(7):875-80. PubMed ID: 26863446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods.
    Kim DH; Kim SM; Hyun JK; Choi MG; Noh JH; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Jul; 20(7):2317-27. PubMed ID: 23677605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.